That's my take, more over when you add Remestemcell-L to the available treatments, we would only be treating those with the high MAP. As we already know that these patients have a 90% chance of not responding to steroids. Remestemcell-L will become a first in line treatment in combination with steroids. When we finally get to test the product on adults we do not need to use jak inhibitors, they would be used as a salvage treatment in those remaining few that do not respond to our therapy.
I would also think it highly likely that MAP biomarkers would be used as a quality attributed between batches.
As a final check on the product for release we would only need to treat 4 patients to have a 90% confidence that the product was highly effective.
Good luck all
- Forums
- ASX - By Stock
- Nature publication
That's my take, more over when you add Remestemcell-L to the...
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
55.5¢ |
Change
0.060(12.1%) |
Mkt cap ! $633.0M |
Open | High | Low | Value | Volume |
50.0¢ | 59.0¢ | 48.5¢ | $16.88M | 30.80M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 62700 | 55.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.0¢ | 40000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 62700 | 0.555 |
11 | 117118 | 0.550 |
4 | 40314 | 0.545 |
9 | 197656 | 0.540 |
2 | 25000 | 0.530 |
Price($) | Vol. | No. |
---|---|---|
0.560 | 40000 | 1 |
0.565 | 310 | 1 |
0.570 | 58775 | 2 |
0.575 | 43000 | 3 |
0.580 | 76419 | 3 |
Last trade - 16.10pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
55.5¢ |
  |
Change
0.060 ( 15.7 %) |
|||
Open | High | Low | Volume | ||
50.5¢ | 59.0¢ | 48.5¢ | 11524458 | ||
Last updated 16.02pm 29/03/2024 ? |
Featured News
MSB (ASX) Chart |